Seoulin Bioscience Co.Ltd (038070) — Cash Flow Quality Index
Seoulin Bioscience Co.Ltd (038070) has a Cash Flow Quality Index of 3.62x as of September 2025. Operating cash flow of ₩2.78 Billion exceeds net income of ₩766.93 Million, indicating high earnings quality where cash backs reported profits. Explore long-term investment intensity of Seoulin Bioscience Co.Ltd to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Seoulin Bioscience Co.Ltd Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Seoulin Bioscience Co.Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Seoulin Bioscience Co.Ltd (038070) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Seoulin Bioscience Co.Ltd (2013–2025)
Year-by-year earnings quality comparison for Seoulin Bioscience Co.Ltd. For live market cap and the full company financial profile, see 038070 market cap overview.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 6.50x | ₩4.76 Billion | ₩731.98 Million | ▲ +542.8% |
| 2024 | -1.47x | ₩-4.61 Billion | ₩3.14 Billion | ▼ -221.7% |
| 2022 | -0.46x | ₩-4.36 Billion | ₩9.54 Billion | ▼ -179.8% |
| 2021 | 0.57x | ₩8.92 Billion | ₩15.59 Billion | ▼ -24.0% |
| 2020 | 0.75x | ₩3.68 Billion | ₩4.89 Billion | ▼ -8.6% |
| 2019 | 0.82x | ₩7.32 Billion | ₩8.88 Billion | ▼ -48.2% |
| 2018 | 1.59x | ₩4.17 Billion | ₩2.62 Billion | ▲ +151.9% |
| 2017 | 0.63x | ₩1.30 Billion | ₩2.06 Billion | ▼ -4.7% |
| 2016 | 0.66x | ₩2.76 Billion | ₩4.16 Billion | ▼ -70.6% |
| 2015 | 2.26x | ₩4.12 Billion | ₩1.83 Billion | ▲ +119.7% |
| 2014 | 1.03x | ₩2.74 Billion | ₩2.67 Billion | ▼ -13.5% |
| 2013 | 1.19x | ₩4.94 Billion | ₩4.16 Billion | — |